The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
Open accessAbstract
Purpose: The significance of radiotherapy (RT) –associated cardiac injury for stage III non–small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study. We assessed the impact of heart dose in patients treated at our institution on several prospective dose-escalation trials. Patients and Methods: From 1996 to 2009, 127 patients with stage III NSCLC (Eastern Cooperative Oncology Group performance status, 0 to 1) received dose-escalated RT to 70 to 90 Gy (median, 74 Gy) in six trials. RT plans and cardiac doses were reviewed. Records were reviewed for the primary end point: symptomatic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, significant arrhythmia, and heart failure). Cardiac risk was assessed by noting baseline coronary artery disease and calculating the WHO/International Society of Hypertension score. Competing risks analysis was used. Results: In all, 112 patients were analyzed. Median follow-up for surviving patients was 8.8 years. Twenty-six patients (23%) had one or more events at a median of 26 months to first event (effusion [n = 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmia [n = 12], and heart failure [n = 1]). Heart doses (eg, heart mean dose; hazard ratio, 1.03/Gy; P = .002,), coronary artery disease ( P < .001), and WHO/International Society of Hypertension score ( P = .04) were associated with events on univariable analysis. Heart doses remained significant on multivariable analysis that accounted for baseline risk. Two-year competing risk–adjusted event rates for patients with heart mean dose < 10 Gy, 10 to 20 Gy, or ≥ 20 Gy were 4%, 7%, and 21%, respectively. Heart doses were not associated with overall survival. Conclusion: Cardiac events were relatively common after high-dose thoracic RT and were independently associated with both heart dose and baseline cardiac risk. RT-associated cardiac toxicity after treatment of stage III NSCLC may occur earlier than historically understood, and heart doses should be minimized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974 · cited 2×
“Third, assessing baseline cardiac risk via the WHO/ISH risk score and baseline CAD is imperfect, but it is still a reasonable and practical approach similar to those used by others.(3,8) Fourth, patients were treated over many years on multiple trials, which introduces treatment heterogeneity.”
BackgroundMethodTutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Self-citationDarby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70251-5 · Cited by 1,049
Cuzick, J., Stewart, H., Rutqvist, L., Houghton, J., Edwards, R., Redmond, C., Peto, R., Baum, M., Fisher, B., & Host, H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.447 · Cited by 889
Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer
Hooning, M. J., Botma, A., Aleman, B. M. P., Baaijens, M. H. A., Bartelink, H., Klijn, J. G. M., Taylor, C. W., & van Leeuwen, F. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk064 · Cited by 861
Factors Affecting Late Mortality From Heart Disease After Treatment of Hodgkin's Disease
Hancock, S. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510160067031 · Cited by 773
Feng, M., Moran, J. M., Koelling, T., Chughtai, A., Chan, J. L., Freedman, L., Hayman, J. A., Jagsi, R., Jolly, S., Larouere, J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.10.058 · Cited by 715
Cited by
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Wang, K., & Tepper, J. E. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21689 · Cited by 449
Self-citation2025 ESC Guidelines for the management of myocarditis and pericarditis
Schulz-Menger, J., Collini, V., Gröschel, J., Adler, Y., Brucato, A., Christian, V., Ferreira, V. M., Gandjbakhch, E., Heidecker, B., Kerneis, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf192 · Cited by 434
Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer
Atkins, K. M., Rawal, B., Chaunzwa, T. L., Lamba, N., Bitterman, D. S., Williams, C. L., Kozono, D. E., Baldini, E. H., Chen, A. B., Nguyen, P. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.500 · Cited by 274
Radiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology
Belzile‐Dugas, E., & Eisenberg, M. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021686 · Cited by 273
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
Banfill, K., Giuliani, M., Aznar, M., Franks, K., McWilliam, A., Schmitt, M., Sun, F., Vozenin, M. C., & Faivre Finn, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.002 · Cited by 272
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Denlinger, C. S., Sanft, T., Baker, K. S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., Goldman, M., Hudson, M., Khakpour, N., King, A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0078 · Cited by 199
Metadata
- Authors
- Wang, K., Eblan, M. J., Deal, A. M., Lipner, M., Zagar, T. M., Wang, Y., Mavroidis, P., Lee, C. B., Jensen, B. C., Rosenman, J. G., Socinski, M. A., Stinchcombe, T. E., & Marks, L. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-05-01
- Volume
- 35
- Issue
- 13
- Pages
- 1387-1394
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2581615902
- Cited by
- 428
- References
- 28
- FWCI
- 35.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.